网站地图 联系我们搜索内部网English | 中国科学院
首页 所况简介 机构设置 科研队伍 科学研究平台 院地合作 党群园地 国际交流 博士后 研究生教育 科学传播 信息公开
学术活动
最新信息
贝时璋讲座
2014年学术活动
2013年学术活动
2012年学术活动
2011年学术活动
2010年学术活动
2009年学术活动
2008年学术活动
2007年学术活动
2006年学术活动
2005年学术活动
2004年学术活动
科学成果
发表论文
专著
专利
获奖
专题
所史丛书
所庆专辑
建所50周年画册
现在位置:首页 > 学术活动 > 2010年学术活动
学术报告:Development of Peptide Therapeutics
2010-12-14 | 【     】【打印】【关闭

报告题目:Development of Peptide Therapeutics

报 告 人:Dr. Gary Woodnutt

      Vice President, CovX of Pfizer

地   点:所图书馆二层报告厅

时  间:2010年3月26日(周五)下午3:00

主 持 人:许瑞明 研究员

报告人简介:

Dr. Gary Woodnutt

Gary Woodnutt received his doctoral degree in Biochemistry and Physiology from Leeds University in 1982. He worked extensively in small molecule Discovery and Development for Infectious Disease and Supportive Care indications while at GlaxoSmithKline, eventually attaining the role of Vice President of Biology in the Anti-Infective Center of Excellence. He moved to oversee Biotherapeutic and Natural Product discovery at Diversa in 2001 expanding the early stage technology into therapies for Oncology and Metabolic Disease. He joint CovX in 2006 to oversee the Biology efforts in early stage discovery and development of therapies for Oncology and Metabolic Disease and was pivotal in the discussions with Pfizer leading to purchase of CovX in 2008. Since the purchase he has been extensively involved in expanding the potential for CovX technology use in other therapeutic areas ( Pain, COPD, anti-infective, Inflammation and Immunology) including the development of bifunctional technology to further expand therapeutic uses and the initiation of Phage Discovery Efforts. Currently Vice president of Biology he continues to expand collaborative links internally with the newly acquired Wyeth organization as well as with Academic and Biotechnology Companies.

报告摘要: 

Peptides have promise as potent and selective drug candidates but have not succeeded primarily because of poor pharmacokinetics. The fusion of these peptides to our scaffold antibody has produced molecules that have the advantage of the peptide activity but with pharmacokinetics determined by the scaffold. Examples will be discussed that have enabled rapid SAR to be carried out producing pre-clinical and clinical candidates with optimized activity and pharmacokinetics.

   

评 论
                 
版权所有:万博APP提款挺快     京ICP备05002792号 京公网安备 110402500011 号
地址:北京市朝阳区大屯路15号(100101) 电话:010-64889872
意见反馈联系人:马秋云 电子邮件:maqiuyun@moon.ibp.ac.cn